The Marginal Liver Donor and Organ Preservation Strategies

  • Coney Bae
  • Scot D. Henry
  • Giridhar Vedula
  • James V. Guarrera
Chapter

Abstract

According to the United Network for Organ Sharing (UNOS) data, as of December 2010, 4,448 liver transplants have been performed with 16,118 patients on the waiting list in the same year [1]. The advances in patient and donor selection, surgical techniques, immunosuppression, organ preservation, and critical care management have made lifesaving liver transplantation possible to those with irrevocable liver damage and acute liver failure. Yet the scarcity of organs continues to be a major obstacle to greater application of liver transplantation (Fig. 15.1).

Keywords

Hepatitis Ischemia Lymphoma Glutathione Superoxide 

References

  1. 1.
    United Network for Organ Sharing. Accessed at http://www.unos.org December 2012.
  2. 2.
    Emre S, Schwartz ME, Altaca G, et al. Safe use of hepatic allografts from donors older than 70 years. Transplantation. 1996;62:62–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Oh CK, Sanfey HA, Pelletier SJ, Sawyer RG, McCullough CS, Pruett TL. Implication of advanced donor age on the outcome of liver transplantation. Clin Transplant. 2000;14:386–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Wall WJ, Mimeault R, Grant DR, Bloch M. The use of older donor livers for hepatic transplantation. Transplantation. 1990;49:377–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoofnagle JH, Lombardero M, Zetterman RK, et al. Donor age and outcome of liver transplantation. Hepatology. 1996;24:89–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Rull R, Vidal O, Momblan D, et al. Evaluation of potential liver donors: limits imposed by donor variables in liver transplantation. Liver Transpl. 2003;9:389–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation. 2007;84:331–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Mutimer DJ, Gunson B, Chen J, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation. 2006;81:7–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Condron SL, Heneghan MA, Patel K, Dev A, McHutchison JG, Muir AJ. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation. 2005;80:145–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Alkofer B, Samstein B, Guarrera JV, et al. Extended-donor criteria liver allografts. Semin Liver Dis. 2006;26:221–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Takeda Y, Arii S, Kaido T, et al. Morphologic alteration of hepatocytes and sinusoidal endothelial cells in rat fatty liver during cold preservation and the protective effect of hepatocyte growth factor. Transplantation. 1999;67:820–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc. 1997;29:412–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Lemasters JJ, Peng XX, Bachmann S, Currin RT, Gao W, Thurman RG. Dual role of Kupffer cell activation and endothelial cell damage in reperfusion injury to livers stored for transplantation surgery. J Gastroenterol Hepatol. 1995;10 Suppl 1:S84–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Markin RS, Wisecarver JL, Radio SJ, et al. Frozen section evaluation of donor livers before transplantation. Transplantation. 1993;56:1403–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Fishbein TM, Fiel MI, Emre S, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation. 1997;64:248–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol. 1996;24:114–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Porte RJ, Ploeg RJ, Hansen B, et al. Long-term graft survival after liver transplantation in the UW era: late effects of cold ischemia and primary dysfunction. European Multicentre Study Group. Transpl Int. 1998;11 Suppl 1:S164–7.PubMedGoogle Scholar
  18. 18.
    Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation–a multivariate analysis. Transplantation. 1993;55:807–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Scotte M, Dousset B, Calmus Y, Conti F, Houssin D, Chapuis Y. The influence of cold ischemia time on biliary complications following liver transplantation. J Hepatol. 1994;21:340–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Yersiz H, Shaked A, Olthoff K, et al. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation. 1995;60:790–4.PubMedGoogle Scholar
  22. 22.
    Castells L, Vargas V, Rodriguez-Frias F, et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc. 1999;31:2464–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Uemoto S, Inomata Y, Sannomiya A, et al. Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors. Transplant Proc. 1998;30:134–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59:230–4.PubMedGoogle Scholar
  25. 25.
    Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol. 1997;26:517–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation. 1997;64:1582–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65:494–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Nery JR, Gedaly R, Vianna R, et al. Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation? Transplant Proc. 2001;33:1521–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Joya-Vazquez PP, Dodson FS, Dvorchik I, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002;73:1598–602.PubMedCrossRefGoogle Scholar
  31. 31.
    Loss GE, Mason AL, Blazek J, et al. Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant. 2001;15 Suppl 6:55–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Salizzoni M, Lupo F, Zamboni F, et al. Outcome of patients transplanted with liver from hepatitis C positive donors. Transplant Proc. 2001;33:1507–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Velidedeoglu E, Desai NM, Campos L, et al. Effect of donor hepatitis C on liver graft survival. Transplant Proc. 2001;33:3795–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–93. discussion 93–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9:1053–61.PubMedCrossRefGoogle Scholar
  36. 36.
    Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317–22.PubMedGoogle Scholar
  37. 37.
    Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Turner BL, Cade-Menun BJ, Condron LM, Newman S. Extraction of soil organic phosphorus. Talanta. 2005;66:294–306.PubMedCrossRefGoogle Scholar
  39. 39.
    Condron CL, Porter R, Guo T, Kauzlarich SM. Crystal structures, Raman spectroscopy, and magnetic properties of Ba7.5Al13Si29 and Eu0.27Ba7.22Al13Si29. Inorg Chem. 2005;44:9185–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Mazzaferro V, Regalia E, Pulvirenti A, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc. 1997;29:519–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–98.PubMedCrossRefGoogle Scholar
  42. 42.
    Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998;65:82–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus ­recurrence after liver transplantation. J Hepatol. 2005;43:53–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant. 2004;18:166–73.PubMedCrossRefGoogle Scholar
  46. 46.
    Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003;124:642–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Berg CL, Steffick DE, Edwards EB, et al. Liver and intestine transplantation in the United States 1998–2007. Am J Transplant. 2009;9:907–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248:599–607.PubMedGoogle Scholar
  49. 49.
    Yamamoto S, Wilczek HE, Duraj FF, Groth CG, Ericzon BG. Liver transplantation with grafts from controlled donors after cardiac death: a 20-year follow-up at a single center. Am J Transplant. 2010;10:602–11.PubMedCrossRefGoogle Scholar
  50. 50.
    Pine JK, Aldouri A, Young AL, et al. Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl. 2009;15:1072–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Grewal HP, Willingham DL, Nguyen J, et al. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl. 2009;15:1028–35.PubMedCrossRefGoogle Scholar
  52. 52.
    Skaro AI, Jay CL, Baker TB, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery. 2009;146:543–52. discussion 52–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation. 2003;75:1659–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant. 2010;10:2512–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9:1929–35.PubMedCrossRefGoogle Scholar
  57. 57.
    Kauffman HM, McBride MA, Cherikh WS, Spain PC, Delmonico FL. Transplant tumor registry: donors with central nervous system tumors1. Transplantation. 2002;73:579–82.PubMedCrossRefGoogle Scholar
  58. 58.
    Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74:358–62.PubMedCrossRefGoogle Scholar
  59. 59.
    Teperman L. Donor-transmitted diseases. Liver Transpl. 2010;16:S40–4.CrossRefGoogle Scholar
  60. 60.
    Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg. 2005;242:314–23. discussion 23–5.PubMedGoogle Scholar
  61. 61.
    Hong JC, Yersiz H, Busuttil RW. Where are we today in split liver transplantation? Curr Opin Organ Transplant. 2011;16:269–73.PubMedCrossRefGoogle Scholar
  62. 62.
    Trotter JF, Gillespie BW, Terrault NA, et al. Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl. 2011;17:409–17.PubMedCrossRefGoogle Scholar
  63. 63.
    Jaeschke H. Molecular mechanisms of hepatic ­ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol. 2003;284:G15–26.PubMedGoogle Scholar
  64. 64.
    Gao W, Bentley RC, Madden JF, Clavien PA. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology. 1998;27:1652–60.PubMedCrossRefGoogle Scholar
  65. 65.
    Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Kupffer cell activation and endothelial cell damage after storage of rat livers: effects of reperfusion. Hepatology. 1991;13:83–95.PubMedGoogle Scholar
  66. 66.
    Vajdová K, Smreková R, Kukan M, Lutterová M, Wsólová L. Bile analysis as a tool for assessing ­integrity of biliary epithelial cells after cold ischemia—reperfusion of rat livers. Cryobiology. 2000;41:145–52.PubMedCrossRefGoogle Scholar
  67. 67.
    Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation. 1992;53:957–78.PubMedCrossRefGoogle Scholar
  68. 68.
    Kupiec-Weglinski JW, Busuttil RW. Ischemia and reperfusion injury in liver transplantation. Transplant Proc. 2005;37:1653–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Jaeschke H. Reactive oxygen and ischemia/reperfusion injury of the liver. Chem Biol Interact. 1991;79:115–36.PubMedCrossRefGoogle Scholar
  70. 70.
    Atalla SL, Toledo-Pereyra LH, MacKenzie GH, Cederna JP. Influence of oxygen-derived free radical scavengers on ischemic livers. Transplantation. 1985;40:584–90.PubMedCrossRefGoogle Scholar
  71. 71.
    Menger MD. Microcirculatory disturbances secondary to ischemia-reperfusion. Transplant Proc. 1995;27:2863–5.PubMedGoogle Scholar
  72. 72.
    McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159–63.PubMedCrossRefGoogle Scholar
  73. 73.
    Momii S, Koga A. Time-related morphological changes in cold-stored rat livers. A comparison of Euro-Collins solution with UW solution. Transplantation. 1990;50:745–50.PubMedCrossRefGoogle Scholar
  74. 74.
    Gebhard MM, Bretschneider HJ, Gersing E, Preusse CJ, Schnabel PA, Ulbricht LJ. Calcium-free cardioplegia—pro. Eur Heart J. 1983;4(Suppl H):151–60.PubMedCrossRefGoogle Scholar
  75. 75.
    Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988;45:673–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Menasche P, Termignon JL, Pradier F, et al. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg. 1994;8:207–13.PubMedCrossRefGoogle Scholar
  77. 77.
    Bessems M, Doorschodt BM, van Vliet AK, van Gulik TM. Machine perfusion preservation of the non-heart-beating donor rat livers using polysol, a new preservation solution. Transplant Proc. 2005;37:326–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant. 2010;10:372–81.PubMedCrossRefGoogle Scholar
  79. 79.
    Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009;360:7–19.PubMedCrossRefGoogle Scholar
  80. 80.
    Lee CY, Zhang JX, Jones Jr JW, Southard JH, Clemens MG. Functional recovery of preserved livers following warm ischemia: improvement by machine perfusion preservation. Transplantation. 2002;74:944–51.PubMedCrossRefGoogle Scholar
  81. 81.
    Iwamoto H, Matsuno N, Narumi Y, et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. Transplant Proc. 2000;32:1645–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Guarrera JV, Henry SD, Chen SW, et al. Hypothermic machine preservation attenuates ischemia/reperfusion markers after liver transplantation: preliminary results. J Surg Res. 2011;167:e365–73.PubMedCrossRefGoogle Scholar
  83. 83.
    Guarrera JV, Karim NA. Liver preservation: is there anything new yet? Curr Opin Organ Transplant. 2008;13:148–54.PubMedCrossRefGoogle Scholar
  84. 84.
    Kaizu T, Nakao A, Tsung A, et al. Carbon monoxide inhalation ameliorates cold ischemia/reperfusion injury after rat liver transplantation. Surgery. 2005;138:229–35.PubMedCrossRefGoogle Scholar
  85. 85.
    Amersi F, Shen XD, Anselmo D, et al. Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology. 2002;35:815–23.PubMedCrossRefGoogle Scholar
  86. 86.
    de Rougemont O, Lehmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver. Liver Transpl. 2009;15:1172–82.PubMedCrossRefGoogle Scholar
  87. 87.
    Tolboom H, Pouw RE, Izamis ML, et al. Recovery of warm ischemic rat liver grafts by normothermic extracorporeal perfusion. Transplantation. 2009;87:170–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Brockmann J, Reddy S, Coussios C, et al. Normothermic perfusion: a new paradigm for organ preservation. Ann Surg. 2009;250:1–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Fondevila C, Hessheimer AJ, Ruiz A, et al. Liver transplant using donors after unexpected cardiac death: novel preservation protocol and acceptance criteria. Am J Transplant. 2007;7:1849–55.PubMedCrossRefGoogle Scholar
  90. 90.
    Henry SD, van der Wegen P, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther. 2006;14:485–93.PubMedCrossRefGoogle Scholar
  91. 91.
    Lehmann TG, Wheeler MD, Froh M, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation. 2003;76: 28–37.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Coney Bae
    • 1
  • Scot D. Henry
    • 1
  • Giridhar Vedula
    • 1
  • James V. Guarrera
    • 1
  1. 1.Division of Abdominal Organ Transplantation and Molecular Therapies and Organ Preservation Research Laboratory, Department of SurgeryColumbia University Medical CenterNew YorkUSA

Personalised recommendations